Incidence and Clinical Significance of Recompensation After HCV Cure

The incidence and clinical significance of recompensation after hepatitis C virus (HCV) cure in patients with decompensated cirrhosis have been a focus of detailed analysis. Here is a comprehensive breakdown based on the given context:

### **Incidence of Recompensation**

1. **Recompensation Rate**: Among patients with decompensated cirrhosis who achieved sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy, approximately **36.6%** achieved recompensation during the follow-up period. This indicates that over one-third of these patients experienced significant clinical improvement.

2. **Time to Recompensation**: The median time to achieve recompensation was **under two years** after HCV cure, suggesting that clinical improvement can occur relatively early following viral eradication.

3. **Definition of Recompensation**: Recompensation was defined using the Baveno VII criteria, which required:

• Etiological cure of HCV.
• Resolution of ascites and hepatic encephalopathy without medication.
• No variceal bleeding for a minimum duration of 12 months.

### **Clinical Significance of Recompensation**

Recompensation is clinically significant as it leads to substantial improvements in patient outcomes, although it does not fully restore the risk profile to the level of compensated advanced chronic liver disease (ACLD).

1. **Reduced Liver-Related Mortality**: Achieving recompensation was associated with a **markedly lower risk of liver-related death** compared to patients who remained decompensated. This highlights the potential for improved survival outcomes.

2. **Improved Overall Survival**: Overall mortality was significantly lower in recompensated patients. However, their survival rates did not reach those of patients with compensated ACLD, indicating that recompensated patients still carry residual risks.

3. **Lower Risk of Portal Vein Thrombosis (PVT)**: Recompensated patients had a **substantially reduced incidence of portal vein thrombosis** compared with non-recompensated individuals. This suggests that recompensation has a positive impact on vascular complications.

4. **Persistent Risk of Hepatocellular Carcinoma (HCC)**: Despite achieving recompensation, the risk of developing hepatocellular carcinoma (HCC) remained **significant** and comparable to that of patients with decompensated cirrhosis. This underscores the need for continued HCC surveillance.

5. **Intermediate Risk Profile**: Recompensated patients demonstrated an **intermediate risk profile** between compensated ACLD and decompensated cirrhosis across major clinical endpoints, such as mortality and complications.

6. **Further Decompensation Risk**: Nearly **one-fifth (20%)** of recompensated patients experienced subsequent redecompensation during follow-up. This indicates that recompensation is not always durable, and vigilance is required even after clinical improvement.

### **Predictors and Barriers to Recompensation**

1. **Positive Predictor - Serum Albumin**: Higher serum albumin levels were independently associated with a greater likelihood of achieving recompensation. Albumin is a key marker of liver function and overall health status.

2. **Negative Predictor - Diabetes**: The presence of diabetes significantly reduced the probability of recompensation after HCV cure. This suggests that metabolic comorbidities can hinder clinical improvement.

3. **MELD Score Not Predictive**: The Model for End-Stage Liver Disease (MELD) score, commonly used to assess liver disease severity, did not independently predict recompensation or long-term outcomes after viral eradication.

4. **HCC as a Barrier**: Development of de novo hepatocellular carcinoma (HCC) prevented recompensation, as no patient achieved recompensation after the onset of HCC.

5. **Alcohol Use**: Ongoing alcohol consumption remained a concern even after HCV cure, potentially limiting the benefits of recompensation and increasing the risk of liver-related complications.

### **Long-Term Management Implications**

1. **Surveillance and Monitoring**: Recompensated patients cannot be managed like those with compensated ACLD due to persistently elevated risks of complications such as HCC and redecompensation. Continued **surveillance for HCC and other complications** is essential.

2. **Alcohol Abstinence**: Addressing alcohol use is critical to maximizing the benefits of recompensation and reducing the risk of further liver damage.

3. **Tailored Clinical Management**: Recompensated patients require individualized management strategies to address their intermediate risk profile and prevent further decompensation.

4. **Durability of Outcomes**: Long-term follow-up (median exceeding eight years in the study) is crucial to assess the durability of recompensation and to identify patients at risk of redecompensation or other adverse outcomes.

### **Conclusion**

Recompensation after HCV cure is a clinically significant outcome, offering substantial improvements in survival, reduced liver-related mortality, and lower risk of complications like portal vein thrombosis. However, recompensation does not eliminate all risks, as patients remain vulnerable to hepatocellular carcinoma, redecompensation, and other complications. Continued surveillance and tailored clinical management are essential for optimizing outcomes in this patient population.